A phase 2 trial of HQK-1001 in HbE-β thalassemia demonstrates HbF induction and reduced anemia

Poramin PatthamalaiSuthat FuchareonNattawara ChaneiamRichard G. GhalieDavid H.K. ChuiMichael S. BoosalisSusan P. PerrineMahidol UniversityHemaQuest PharmaceuticalsBoston University School of Medicine2018-11-092018-11-092014-03-20Blood. Vol.123, No.12 (2014), 1956-195715280020000649712-s2.0-84897487469https://repository.li.mahidol.ac.th/handle/123456789/33285Mahidol UniversityBiochemistry, Genetics and Molecular BiologyImmunology and MicrobiologyMedicineA phase 2 trial of HQK-1001 in HbE-β thalassemia demonstrates HbF induction and reduced anemiaLetterSCOPUS10.1182/blood-2013-11-538470